BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care
BD (NYSE: BDX) has announced a $35 million investment to expand its prefilled flush syringe manufacturing capacity at its Columbus, Nebraska facility. The expansion will create approximately 50 new jobs and increase production of BD庐 PosiFlush鈩� Prefilled Flush Syringes by hundreds of millions of units annually.
The company has already invested over $80 million in the past three years, increasing U.S. production by more than 750 million units, including a 10% increase this year. This investment is part of BD's larger $2.5 billion commitment to enhance U.S. manufacturing capacity over the next five years.
The Columbus facility, operating for over 75 years, is the largest manufacturer of prefilled flush devices in the U.S. BD currently operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.
BD (NYSE: BDX) ha annunciato un investimento di 35 milioni di dollari per ampliare la capacit脿 produttiva di siringhe pre-riempite per lavaggio presso il suo stabilimento di Columbus, Nebraska. L'espansione creer脿 circa 50 nuovi posti di lavoro e aumenter脿 la produzione delle siringhe pre-riempite BD庐 PosiFlush鈩� di centinaia di milioni di unit脿 all'anno.
Negli ultimi tre anni, l'azienda ha gi脿 investito oltre 80 milioni di dollari, incrementando la produzione negli Stati Uniti di pi霉 di 750 milioni di unit脿, con un aumento del 10% solo quest'anno. Questo investimento fa parte del pi霉 ampio impegno da 2,5 miliardi di dollari di BD per potenziare la capacit脿 produttiva negli Stati Uniti nei prossimi cinque anni.
Lo stabilimento di Columbus, attivo da oltre 75 anni, 猫 il pi霉 grande produttore di dispositivi pre-riempiti per lavaggio negli USA. BD gestisce attualmente pi霉 di 30 stabilimenti di produzione e distribuzione negli Stati Uniti, distribuiti in 17 stati e a Porto Rico, con oltre 10.000 dipendenti.
BD (NYSE: BDX) ha anunciado una inversi贸n de 35 millones de d贸lares para ampliar su capacidad de fabricaci贸n de jeringas prellenadas para lavado en su planta de Columbus, Nebraska. La expansi贸n crear谩 aproximadamente 50 nuevos empleos y aumentar谩 la producci贸n anual de las jeringas prellenadas BD庐 PosiFlush鈩� en cientos de millones de unidades.
La compa帽铆a ya ha invertido m谩s de 80 millones de d贸lares en los 煤ltimos tres a帽os, incrementando la producci贸n en EE. UU. en m谩s de 750 millones de unidades, incluyendo un aumento del 10% este a帽o. Esta inversi贸n forma parte del mayor compromiso de 2.500 millones de d贸lares de BD para mejorar la capacidad manufacturera en EE. UU. en los pr贸ximos cinco a帽os.
La planta de Columbus, en funcionamiento durante m谩s de 75 a帽os, es el mayor fabricante de dispositivos prellenados para lavado en EE. UU. Actualmente, BD opera m谩s de 30 instalaciones de fabricaci贸n y distribuci贸n en 17 estados y Puerto Rico, empleando a m谩s de 10,000 personas.
BD (NYSE: BDX)電� 雱る笇霝橃姢旃挫＜ 旖滊熂氩勳姢 鞁滌劋鞐愳劀 頂勲Μ頃勲摐 頂岆煬鞁� 欤检偓旮� 鞝滌“ 電ル牓鞚� 頇曥灔頃橁赴 鞙勴暣 3,500毵� 雼煬 韴瀽毳� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 頇曥灔鞙茧 鞎� 50臧滌潣 鞁犼窚 鞚检瀽毽�臧� 彀届稖霅橂┌, BD庐 PosiFlush鈩� 頂勲Μ頃勲摐 頂岆煬鞁� 欤检偓旮办潣 鞐瓣皠 靸濎偘霟夓澊 靾橃柕 雼渼搿� 歃濌皜頃� 鞓堨爼鞛呺媹雼�.
須岇偓電� 歆�雮� 3雲勱皠 鞚措 8,000毵� 雼煬 鞚挫儊鞚� 韴瀽頃橃棳 氙戈淡 雮� 靸濎偘霟夓潉 7鞏� 5觳滊 雼渼 鞚挫儊 歃濌皜鞁滌及鞙茧┌, 鞓暣鞐愲姅 10% 歃濌皜毳� 旮半頄堨姷雼堧嫟. 鞚措矆 韴瀽電� 頄ロ泟 5雲勱皠 氙戈淡 鞝滌“ 電ル牓 臧曧檾毳� 鞙勴暅 BD鞚� 25鞏� 雼煬 攴滊鞚� 鞎届啀鞚� 鞚柬櫂鞛呺媹雼�.
75雲� 鞚挫儊 鞖挫榿霅� 旖滊熂氩勳姢 鞁滌劋鞚� 氙戈淡鞐愳劀 臧�鞛� 韥� 頂勲Μ頃勲摐 頂岆煬鞁� 鞛レ箻 鞝滌“鞐呾泊鞛呺媹雼�. BD電� 順勳灛 17臧� 欤检檧 響胳棎毳错啝毽綌鞐� 瓯胳硱 30臧� 鞚挫儊鞚� 鞝滌“ 氚� 鞙犿喌 鞁滌劋鞚� 鞖挫榿頃橂┌ 10,000氇� 鞚挫儊鞚� 歆侅洂鞚� 瓿犾毄頃橁碃 鞛堨姷雼堧嫟.
BD (NYSE : BDX) a annonc茅 un investissement de 35 millions de dollars pour augmenter sa capacit茅 de production de seringues pr茅remplies pour rin莽age dans son usine de Columbus, Nebraska. Cette expansion cr茅era environ 50 nouveaux emplois et augmentera la production annuelle des seringues pr茅remplies BD庐 PosiFlush鈩� de plusieurs centaines de millions d鈥檜nit茅s.
L鈥檈ntreprise a d茅j脿 investi plus de 80 millions de dollars au cours des trois derni猫res ann茅es, augmentant la production aux 脡tats-Unis de plus de 750 millions d鈥檜nit茅s, avec une hausse de 10 % cette ann茅e. Cet investissement s鈥檌nscrit dans le cadre de l鈥檈ngagement plus large de BD de 2,5 milliards de dollars pour renforcer la capacit茅 de fabrication aux 脡tats-Unis au cours des cinq prochaines ann茅es.
L鈥檜sine de Columbus, en activit茅 depuis plus de 75 ans, est le plus grand fabricant d鈥檃ppareils de rin莽age pr茅remplis aux 脡tats-Unis. BD exploite actuellement plus de 30 sites de fabrication et de distribution aux 脡tats-Unis, r茅partis dans 17 脡tats et 脿 Porto Rico, employant plus de 10 000 personnes.
BD (NYSE: BDX) hat eine Investition von 35 Millionen US-Dollar angek眉ndigt, um die Produktionskapazit盲t f眉r vorgef眉llte Sp眉lspritzen an seinem Standort in Columbus, Nebraska, zu erweitern. Die Erweiterung wird etwa 50 neue Arbeitspl盲tze schaffen und die Produktion der BD庐 PosiFlush鈩� vorgef眉llten Sp眉lspritzen j盲hrlich um mehrere hundert Millionen Einheiten erh枚hen.
Das Unternehmen hat in den letzten drei Jahren bereits 眉ber 80 Millionen US-Dollar investiert und die US-Produktion um mehr als 750 Millionen Einheiten gesteigert, darunter eine 10% Steigerung in diesem Jahr. Diese Investition ist Teil von BDs gr枚脽erem 2,5 Milliarden US-Dollar Engagement, die Produktionskapazit盲ten in den USA in den n盲chsten f眉nf Jahren auszubauen.
Die Anlage in Columbus, die seit 眉ber 75 Jahren in Betrieb ist, ist der gr枚脽te Hersteller von vorgef眉llten Sp眉lger盲ten in den USA. BD betreibt derzeit mehr als 30 Produktions- und Vertriebsstandorte in 17 Bundesstaaten und Puerto Rico und besch盲ftigt 眉ber 10.000 Mitarbeiter.
- Investment of $35 million to expand U.S. manufacturing capacity
- Creation of approximately 50 new jobs in Nebraska
- Production increase of hundreds of millions of additional units annually
- Previous investments led to 750 million unit increase and 10% growth this year
- Part of larger $2.5 billion U.S. manufacturing investment plan
- None.
Insights
BD's $35M investment in Nebraska expands manufacturing capacity of critical medical supplies, strengthening US healthcare supply resilience.
BD's
The investment is particularly significant as it addresses supply chain resilience for products that directly impact patient safety. Prefilled flush syringes are essential for catheter maintenance and medication delivery, where any contamination can have severe consequences. BD's fully automated manufacturing process - where the first human touch comes from the clinician - provides a competitive advantage in quality assurance for these direct-to-bloodstream products.
This announcement isn't isolated but part of BD's larger strategic initiative. The company has invested
This capital deployment aligns with industry trends toward reshoring medical device production following pandemic-related supply disruptions. With over 30 US manufacturing and distribution facilities across 17 states employing 10,000+ people, BD is positioning itself as an essential component of US healthcare infrastructure while potentially capturing market share from competitors with less domestic production capability.
The investments will support new BD庐 PosiFlush鈩�听Prefilled Flush Syringe听production lines, product innovation and operational efficiencies, enabling BD to produce hundreds of millions of additional units annually to meet growing demand from
"BD PosiFlush鈩� Syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications," said Eric Borin, worldwide president of BD Medication Delivery Solutions. "Our latest investments boost
Prefilled flush devices like PosiFlush鈩� Prefilled Flush Syringes are used in nearly every hospital across the country as part of catheter care and maintenance to help prevent catheter-related complications and support efficient, high-quality patient care. Quality in manufacturing is critical as these devices deliver fluid directly into a patient's bloodstream, where any contamination or defect can have serious, even fatal, consequences.
PosiFlush鈩� Prefilled Flush Syringes are manufactured using a fully automated, hands-free process, ensuring that the first person to touch the syringe is the clinician 鈥� helping to reduce the potential for contamination. Every syringe is inspected using a rigorous, multi-step, end-to-end inspection process to meet high quality standards for patients and providers.
Over the past three years, BD has invested more than
This announcement builds on the company's broader commitment to strengthening
BD operates more than 30 U.S. manufacturing and distribution facilities across 17 states and
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at , X (formerly Twitter) or Instagram .听
颁辞苍迟补肠迟蝉:听 | |
Media: | Investors: |
Alyssa Kretlow | Adam Reiffe |
BD Public Relations | Sr. Director, Investor Relations |
551.238.4391 | 201.847.6927听听听听听听听听 |
[email protected]听听听听听 |
听
View original content to download multimedia:
SOURCE BD (Becton, Dickinson and Company)
FAQ
What is BD's new investment in Nebraska manufacturing facility?
How many additional jobs will BD (NYSE: BDX) create with this expansion?
What is BD's total planned investment in U.S. manufacturing over the next five years?
How much has BD increased its PosiFlush production in recent years?
How many U.S. manufacturing facilities does BD operate?
